Skip to search formSkip to main contentSkip to account menu

SM 368229

Known as: SM-368229, SM368229 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
449 SM-368229, A MINERALOCORTICOID RECEPTOR ANTAGONIST WITH MODERATE PARTIAL AGONISTIC ACTIVITY SHOWS ANTI-HYPERTENSIVE EFFICACY WITH MINIMAL EFFECT ON SERUM POTASSIUM LEVEL IN RATS
Objective: Mineralocorticoid receptor (MR) antagonists, such as spironolactone and eplerenone, have a serious side effect… 
2011
2011
SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
Mineralocorticoid receptor (MR) antagonists, such as spironolactone (SPI) and eplerenone (EPL), are useful for the treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)